Adagene Inc. Stock Price, News & Analysis

Adagene Inc. (Nasdaq: ADAG) announced a collaboration with Roche to evaluate its ADG126 in combination with Roche's atezolizumab and bevacizumab for treating advanced hepatocellular carcinoma (HCC). The trial will be a randomized phase 1b/2 study, initially involving 60 patients. Adagene retains global rights for ADG126. This collaboration seeks to improve treatment efficacy in a disease with a high mortality rate, leveraging Adagene's SAFEbody technology to enhance safety and efficacy while addressing the challenges of combining therapies.

Adagene Inc. (Nasdaq: ADAG) announced interim phase 1b/2 clinical data for its anti-CTLA-4 antibody ADG116, showcased at the Society for Immunotherapy of Cancer Annual Meeting. Significant findings include: two partial responses in Kaposi’s sarcoma and renal cell carcinoma as monotherapy, and a confirmed durable complete response in head and neck cancer when combined with toripalimab. Additionally, ADG116 demonstrated a potent activity in microsatellite-stable colorectal cancer, with no dose-limiting toxicities reported. The overall disease control rate reached 33% across monotherapy dose levels.

Adagene Inc. (Nasdaq: ADAG) has announced the presentation of clinical data for its anti-CTLA-4 antibody candidate, ADG116, at the SITC Annual Meeting on November 10, 2022. The phase 1b/2 studies demonstrate a differentiated safety profile across dosing levels, including monotherapy and combination with anti-PD-1 therapies. Notably, the data highlights anti-tumor activity in both warm and cold tumors, as well as objective responses in tumor types lacking approved anti-CTLA-4 treatments. The findings will be available on Adagene's website post-presentation.

Adagene Inc. (Nasdaq: ADAG) has showcased the promising results of its drug ADG126 at the ESMO Congress 2022. Interim data from an ongoing Phase 1/2 trial indicates that ADG126, an innovative anti-CTLA-4 SAFEbody®, demonstrates a solid safety profile with no significant adverse effects reported at doses up to 20 mg/kg. Notably, antitumor activity was observed in cold tumors, highlighted by a patient with ovarian cancer showing a 90% drop in the biomarker CA125. Ongoing trials aim to further evaluate ADG126 in combination with anti-PD-1 therapies.

Adagene Inc. (Nasdaq: ADAG) reported positive topline results for its anti-CTLA-4 antibody, ADG116, showing safety and clinical responses in combination with anti-PD-1 therapy. Regulatory filing for ADG206's clinical trial is underway, with patient dosing planned for early 2023. Financially, the company holds US$168 million in cash, sufficient to support operations into late 2024. Notably, net revenue increased to US$3.9 million for H1 2022, rising from US$1.4 million in 2021, aided by collaborations with Sanofi and Exelixis.

Adagene Inc. (Nasdaq: ADAG) announced a share repurchase program allowing up to US$10 million in buybacks of its ordinary shares. This 2022 Share Repurchase Program enables Adagene to repurchase shares at prevailing market prices through various means, subject to market conditions and regulatory requirements. The program will commence upon agreement with a broker-dealer and lasts for twelve months. Adagene aims to utilize existing funds for this initiative, signaling confidence in its share value and long-term market strategy.

Adagene Inc. (Nasdaq: ADAG) announced promising interim results for its anti-CTLA-4 monoclonal antibody, ADG126, at the ASCO 2022 meeting. The ongoing Phase 1 trial shows no dose-limiting toxicities and only mild treatment-related adverse events in 16 heavily pretreated patients. Two patients demonstrated significant tumor reduction, with one experiencing a 77% decrease in CA-125 levels. Adagene aims to confirm ADG126's safety in combination with anti-PD-1 therapies in upcoming analyses while continuing dose escalation and expansion in the study.

Adagene Inc. (Nasdaq: ADAG) will participate in several upcoming investor conferences, including a live Fireside Chat at the Jefferies Global Healthcare Conference on June 8 at 4:30 p.m. ET and one-on-one meetings at the Goldman Sachs Annual Global Healthcare Conference on June 13. Additionally, Adagene will engage in virtual meetings during the ICA 2nd Annual Asia Pacific Healthcare Conference from May 18-24 and the Berenberg Emerging Biotech Conference on May 19. The company focuses on developing novel antibody-based cancer immunotherapies utilizing advanced technologies.

Adagene Inc. (Nasdaq: ADAG) presented promising preclinical data at the AACR Annual Meeting 2022, showcasing its new antibody candidates designed for improved cancer therapy. The showcased candidates include ADG206, a masked anti-CD137 therapy, ADG153, a masked anti-CD47 antibody, and ADG138, a HER2×CD3 bispecific T-cell engager. All candidates incorporate SAFEbody technology for enhanced safety and efficacy. IND filings for ADG206 and ADG153 are expected in 2022, marking a significant milestone towards advancing these innovative therapies.